Liquid Biopsies in Follicular Thyroid Carcinomas—A Brief Report

Marie-Louise Uhre Hansen; Simone Kloch Bendtsen; Kathrine Kronberg Jakobsen; Ane Yde Schmidt; Christoffer Holst Hahn; Christian von Buchwald; Christian Grønhøj

doi:10.3390/diagnostics14141577

Diagnostics (Jul 2024)

Liquid Biopsies in Follicular Thyroid Carcinomas—A Brief Report

Marie-Louise Uhre Hansen,
Simone Kloch Bendtsen,
Kathrine Kronberg Jakobsen,
Ane Yde Schmidt,
Christoffer Holst Hahn,
Christian von Buchwald,
Christian Grønhøj

Affiliations

Marie-Louise Uhre Hansen: Department of Otorhinolaryngology, Head and Neck Surgery and Audiology, Copenhagen University Hospital, Rigshospitalet, 2100 Copenhagen, Denmark
Simone Kloch Bendtsen: Department of Otorhinolaryngology, Head and Neck Surgery and Audiology, Copenhagen University Hospital, Rigshospitalet, 2100 Copenhagen, Denmark
Kathrine Kronberg Jakobsen: Department of Otorhinolaryngology, Head and Neck Surgery and Audiology, Copenhagen University Hospital, Rigshospitalet, 2100 Copenhagen, Denmark
Ane Yde Schmidt: Center for Genomic Medicine, Copenhagen University Hospital, Rigshospitalet, 2100 Copenhagen, Denmark
Christoffer Holst Hahn: Department of Otorhinolaryngology, Head and Neck Surgery and Audiology, Copenhagen University Hospital, Rigshospitalet, 2100 Copenhagen, Denmark
Christian von Buchwald: Department of Otorhinolaryngology, Head and Neck Surgery and Audiology, Copenhagen University Hospital, Rigshospitalet, 2100 Copenhagen, Denmark
Christian Grønhøj: Department of Otorhinolaryngology, Head and Neck Surgery and Audiology, Copenhagen University Hospital, Rigshospitalet, 2100 Copenhagen, Denmark

DOI: https://doi.org/10.3390/diagnostics14141577
Journal volume & issue: Vol. 14, no. 14
p. 1577

Abstract

Read online

Thyroid cancer (TC) represents a significant health burden globally, with follicular thyroid cancer (FTC) posing diagnostic challenges despite advancements. This pilot study aimed to evaluate the utility of a liquid biopsy with cell-free DNA (cfDNA) in patients with FTC. Blood samples were collected from 13 patients diagnosed with FTC, DNA extraction was performed, and cfDNA was analyzed using the Illumina’s TruSight Oncology 500 High-Throughput panel. The results revealed low tumor mutational burden and minimal pathogenic variants in cfDNA, indicating challenges such as low DNA yield and poor material quality despite adequate coverage. Our findings indicate that cfDNA as an add-on diagnostic tool in patients with FTC might not be a useful supplement.

Published in Diagnostics

ISSN: 2075-4418 (Online)
Publisher: MDPI AG
Country of publisher: Switzerland
LCC subjects: Medicine: Medicine (General)
Website: http://www.mdpi.com/journal/diagnostics

About the journal

Abstract

Keywords